Day 2 of @CVCTForum #CVCT2020
Use of biomarkers in clinical trials!!!
Lawrence Fine from NIH on pros and cons of biomarkers in trials. Do they help overcome challenges and reduce sample size?
Use of biomarkers in clinical trials!!!
Lawrence Fine from NIH on pros and cons of biomarkers in trials. Do they help overcome challenges and reduce sample size?
Charalambos Antoniades now reviews imaging endpoints in atherosclerosis and also inflammatory residual risk.
Not only plaque burden but also Fat Attenuation Index of the perivascular adipose tissue
Not only plaque burden but also Fat Attenuation Index of the perivascular adipose tissue
- FAI is increased in inflammatory diseases such as psoriasis
- Statins improve FAI
- FAI restratifies individuals without high-risk plaque features
- Statins improve FAI
- FAI restratifies individuals without high-risk plaque features
Sandra Sanders now discusses biomarkers in HF and polypharmacy
Given that BNP-guided therapy failed in GUIDE-IT trial, do we need them?
Given that BNP-guided therapy failed in GUIDE-IT trial, do we need them?